Boehringer’s obesity candidate survodutide shows strong potential in MASH
Boehringer Ingelheim on Monday revealed new Phase II data for its investigational GLP-1/glucagon receptor dual agonist survodutide, showing that it could elicit significant improvements in patients with metabolic dysfunction-associated steatohepatitis.